TY - JOUR
T1 - High-dose cyclophosphamide, carboplatin, and etoposide with autologous stem cell rescue in patients with breast cancer
AU - DeMagalhaes-Silverman, Margarida
AU - Rybka, Witold B.
AU - Lembersky, Barry
AU - Bloom, Elana J.
AU - Lister, John
AU - Pincus, Steven M.
AU - Voloshin, Michael
AU - Wilson, John
AU - Ball, Edward D.
PY - 1996/4
Y1 - 1996/4
N2 - This study was designed to establish the toxicity and response rates observed with a combination of high-dose cyclophosphamide, carboplatin, and etoposide with stem cell rescue in patients with breast carcinoma. Eligibility criteria included metastatic or locally advanced breast carcinoma; aged ≤60 years; performance status Eastern Cooperative Oncology Group (ECOG) 0-1; and creatinine clearance ≥65 ml/min. Chemotherapy consisted of cyclophosphamide 25 mg/kg i.v. x 4 days, etoposide 400 mg/m2 i.v. x 4 days, and carboplatin 375 mg/m2 x 4 days. Bone marrow or peripheral blood stem cells were reinfused 48 h after completion of chemotherapy. Seventeen patients were treated in this study. The major toxicity was gastrointestinal (grades I and II). Fevers associated with neutropenia were observed in all the patients, but no episodes of bacteremia were documented. Hematopoietic toxicities were acceptable. No toxic deaths were observed. Six patients had chemotherapy-sensitive disease at time of transplant, nine had refractory disease, and two were untested. A response rate of 62% with 18% complete response (CR) was achieved. Two patients are free of disease at +7 and +9 months after transplantation. The combination of high-dose cyclophosphamide, carboplatin, and etoposide is well tolerated with a response rate comparable to previously reported high-dose chemotherapy regimens. However, in a poor prognostic risk group, namely patients with chemoinsensitive disease, this therapeutic approach seems to be of no advantage over standard chemotherapy.
AB - This study was designed to establish the toxicity and response rates observed with a combination of high-dose cyclophosphamide, carboplatin, and etoposide with stem cell rescue in patients with breast carcinoma. Eligibility criteria included metastatic or locally advanced breast carcinoma; aged ≤60 years; performance status Eastern Cooperative Oncology Group (ECOG) 0-1; and creatinine clearance ≥65 ml/min. Chemotherapy consisted of cyclophosphamide 25 mg/kg i.v. x 4 days, etoposide 400 mg/m2 i.v. x 4 days, and carboplatin 375 mg/m2 x 4 days. Bone marrow or peripheral blood stem cells were reinfused 48 h after completion of chemotherapy. Seventeen patients were treated in this study. The major toxicity was gastrointestinal (grades I and II). Fevers associated with neutropenia were observed in all the patients, but no episodes of bacteremia were documented. Hematopoietic toxicities were acceptable. No toxic deaths were observed. Six patients had chemotherapy-sensitive disease at time of transplant, nine had refractory disease, and two were untested. A response rate of 62% with 18% complete response (CR) was achieved. Two patients are free of disease at +7 and +9 months after transplantation. The combination of high-dose cyclophosphamide, carboplatin, and etoposide is well tolerated with a response rate comparable to previously reported high-dose chemotherapy regimens. However, in a poor prognostic risk group, namely patients with chemoinsensitive disease, this therapeutic approach seems to be of no advantage over standard chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=0030005174&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030005174&partnerID=8YFLogxK
U2 - 10.1097/00000421-199604000-00016
DO - 10.1097/00000421-199604000-00016
M3 - Article
C2 - 8610643
AN - SCOPUS:0030005174
SN - 0277-3732
VL - 19
SP - 169
EP - 173
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 2
ER -
